Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services | News
Search Refinements

Contract Services News

View news from other Pharmaceutical sectors:
31-45 of 2369 results
Grünenthal to buy rights to PNP drug from Astellas Pharma Europe
Grünenthal has agreed to acquire commercialization rights of Qutenza in Europe from Astellas Pharma Europe.
Contract Research & Services > Contract Services > News
AstraZeneca, Eli Lilly partner for another Alzheimer's drug
By PBR Staff Writer
Pharmaceutical giants AstraZeneca and Eli Lilly are expanding their collaboration to develop an experimental Alzheimer's drug.
Contract Research & Services > Contract Services > News
Sermonix signs licensing deal to further explore lasofoxifene for breast cancer treatment
Sermonix Pharmaceuticals has signed a licensing agreement to gain exclusive rights to Duke University intellectual property related to the use of lasofoxifene, its lead investigational drug, in the treatment of endocrine-resistant breast cancer.
Contract Research & Services > Contract Services > News
Purdue Pharma, AnaBios partner to advance research for non-opioid, non-NSAID compounds
Purdue Pharma and AnaBios have partnered to advance the research of non-opioid, non-NSAID compounds for the treatment of chronic pain.
Contract Research & Services > Contract Services > News
Aegerion Pharmaceuticals signs licensing deal with Amryt Pharma for Lojuxta
Novelion Therapeutics' subsidiary, Aegerion Pharmaceuticals has entered into a licensing agreement with Amryt Pharma (“Amryt”) for the exclusive rights to LOJUXTA (lomitapide) hard capsules in certain European and Middle Eastern territories.
Contract Research & Services > Contract Services > News
Natrix collaborates with Merck and Sanofi on Protein A Platform
Natrix Separations has signed development agreements with Merck and Sanofi to advance its new membrane-based Protein A platform for antibody purification.
Contract Research & Services > Contract Services > News
Mylan signs deal with Medicines Patent Pool to expand access to hepatitis C medicines in developing countries
Mylan has signed an agreement with the Medicines Patent Pool (MPP) to expand access to chronic hepatitis C medicines in developing countries.
Contract Research & Services > Contract Services > News
Orchard Therapeutics and UCLA secure $20m funding from California’s stem cell agency
The California Institute for Regenerative Medicine’s governing board (CIRM) has awarded $20m to Orchard Therapeutics and researchers from the UCLA Broad Stem Cell Research, led by Orchard Scientific Advisory Board member Donald Kohn.
Contract Research & Services > Contract Services > News
BioLineRx secures rights to DES treatment from Hebrew University
BioLineRx has signed an exclusive, worldwide agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, for the in-licensing of a novel anti-inflammatory treatment for Dry Eye Syndrome (DES).
Contract Research & Services > Contract Services > News
MedImmune completes out-licensing deal with Allergan for MEDI2070
AstraZeneca's global biologics research and development arm, MedImmune has completed out-licensing agreement with Allergan for the global rights to MEDI2070.
Contract Research & Services > Contract Services > News
Grünenthal acquires US-based Thar Pharmaceuticals
Germany-based Grünenthal has acquired US clinical-stage, specialty pharmaceutical firm Thar Pharmaceuticals.
Contract Research & Services > Contract Services > News
Bristol-Myers, Infinity partner for Opdivo- IPI-549 combo trial in advanced solid tumors
By PBR Staff Writer
Bristol-Myers Squibb is evaluating its Opdivo (nivolumab) cancer drug in combination with Infinity Pharmaceuticals’ IPI-549 immuno-oncology development candidate in patients with advanced solid tumors.
Contract Research & Services > Contract Services > News
Lexicon acquires rights to neuropathic pain candidate developed with BMS
Lexicon Pharmaceuticals has obtained exclusive research, development and commercialization rights to LX9211 (BMS-986176), a development candidate for neuropathic pain that was jointly developed by Lexicon and Bristol-Myers Squibb (BMS) as part of their neuroscience drug discovery alliance.
Contract Research & Services > Contract Services > News
EnBiotix purchases AMP Therapeutics' anti-microbial peptide portfolio
EnBiotix has completed an asset acquisition of AMP Therapeutics (AMPT), an anti-microbial peptide portfolio firm of Boehringer Ingelheim Venture Fund and Novartis Venture Fund.
Contract Research & Services > Contract Services > News
Medivir agrees to buy two clinical stage oncology programs from Tetralogic
Medivir has agreed to acquire two clinical stage oncology programs from Tetralogic Pharmaceuticals, advancing and expanding its clinical pipeline.
Contract Research & Services > Contract Services > News
31-45 of 2369 results